Predicting Central Lymph Node Metastasis in Papillary Thyroid Carcinoma Combined with Hashimoto's Thyroiditis: a Preoperative Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2025 Mar 11

PMID 40065226

Authors

Pengwei Lou

Yuting Huang

Hui Li

Feng Zhao

Jiabo Xu

Kai Wang

Affiliations

Soon will be listed here.

Abstract

Background: Current studies have reported a high association between the Hashimoto's thyroiditis (HT) and papillary thyroid cancer (PTC). However, studies on the characteristics of central lymph node metastasis (CLNM) in PTC patients with HT are scarce. Therefore, this study aims to evaluate the risk factors of CLNM in PTC and HT patients.

Methods: We retrospectively collected clinical data from 933 PTC patients with HT who underwent thyroid surgery. Of these, 653 patients were categorized into a training cohort for constructing the nomogram, and 280 patients formed a validation cohort to verify the performance of the model. Least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression analyses were used to select risk factors. A nomogram model for predicting CLNM was developed and internally validated. We subsequently evaluated thyroid function within 3 years after surgery and estimated the prevalence and incidence of postoperative complications between the CLNM ( +) and CLNM (-) groups.

Results: LASSO regression revealed that 19 nonzero variables were associated with CLNM. Multivariate logistic regression analysis revealed that younger, patients of low body mass index (BMI), drinking, intranodular hyperechoic (IH) status, diameter ≥ 1 cm, multifocality, extrathyroidal extension (ETE), enlarged central lymph nodes (ECLNs) and lateral lymph node metastasis (LLNM) were at higher risk of CLNM (P < 0.05). A nomogram to predict CLNM in PTC patients with HT was constructed and internally validated on the basis of risk factors. The areas under the ROC curve (AUCs) of nomogram were 0.768 (95% CI, 0.723-0.812) and 0.773 (95% CI, 0.705-0.841) in training and validation groups, respectively. Moreover, the nomogram data showed a good discrimination and calibration ability to training and validation groups. Postoperative follow-up revealed that TGAb levels and the incidence of hypothyroidism were significantly greater in CLNM ( +) group than CLNM (-) group, respectively.

Conclusions: Our nomogram schedule developed and validated with a comprehensive set of preoperative risk factors showed a high benefit in predicting CLNM in PTC patients with HT. Postoperative follow-up of thyroid function allow to clarify the trend, as well as prevalence and incidence of common thyroid complications.

References

Mohamed H, Mohamed S, Anwar M, Al-Qurayshi Z, Sholl A, Thethi T . The significance of enlarged cervical lymph nodes in diagnosing thyroid cancer. J Cancer Res Ther. 2016; 12(2):1006-9. DOI: 10.4103/0973-1482.171360. View

Feng J, Ye J, Hong L, Hu J, Wang F, Liu S . Nomograms for the prediction of lateral lymph node metastasis in papillary thyroid carcinoma: Stratification by size. Front Oncol. 2022; 12:944414. PMC: 9554485. DOI: 10.3389/fonc.2022.944414. View

Tamimi D . The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol. 2002; 10(2):141-6. DOI: 10.1177/106689690201000207. View

Kim J, Roh J, Gong G, Cho K, Choi S, Nam S . Extent of Extrathyroidal Extension as a Significant Predictor of Nodal Metastasis and Extranodal Extension in Patients with Papillary Thyroid Carcinoma. Ann Surg Oncol. 2016; 24(2):460-468. DOI: 10.1245/s10434-016-5594-4. View

Lee J, Kim Y, Choi J, Kim Y . The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis. Eur J Endocrinol. 2012; 168(3):343-9. DOI: 10.1530/EJE-12-0903. View

Su J, Miao L, Ye X, Cui M, He X . Development of prognostic signature and nomogram for patients with breast cancer. Medicine (Baltimore). 2019; 98(11):e14617. PMC: 6426514. DOI: 10.1097/MD.0000000000014617. View

Bae M, Nam S, Roh J, Choi S, Nam S, Kim S . Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma. Endocrine. 2021; 75(2):487-494. DOI: 10.1007/s12020-021-02911-x. View

Ahmed R, Al-Shaikh S, Akhtar M . Hashimoto thyroiditis: a century later. Adv Anat Pathol. 2012; 19(3):181-6. DOI: 10.1097/PAP.0b013e3182534868. View

Ehlers M, Schott M . Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?. Trends Endocrinol Metab. 2014; 25(12):656-64. DOI: 10.1016/j.tem.2014.09.001. View

10.

Moo T, McGill J, Allendorf J, Lee J, Fahey 3rd T, Zarnegar R . Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg. 2010; 34(6):1187-91. DOI: 10.1007/s00268-010-0418-3. View

11.

Takami H, Ito Y, Okamoto T, Yoshida A . Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg. 2010; 35(1):111-21. DOI: 10.1007/s00268-010-0832-6. View

12.

Ross P, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani P . Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol. 2002; 20(2):82-8. DOI: 10.1053/suro.2002.32490. View

13.

Vasileiadis I, Boutzios G, Charitoudis G, Koukoulioti E, Karatzas T . Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann Surg Oncol. 2014; 21(8):2725-32. DOI: 10.1245/s10434-014-3593-x. View

14.

Liu Q, Pang W, Dong Y, Wang Z, Yu M, Huang X . Analysis of risk factors for lateral lymph node metastasis in papillary thyroid carcinoma: A retrospective cohort study. World J Otorhinolaryngol Head Neck Surg. 2022; 8(3):274-278. PMC: 9479478. DOI: 10.1016/j.wjorl.2021.01.002. View

15.

Ferreira L, Gimba E, Vinagre J, Sobrinho-Simoes M, Soares P . Molecular Aspects of Thyroid Calcification. Int J Mol Sci. 2020; 21(20). PMC: 7589718. DOI: 10.3390/ijms21207718. View

16.

Xiang T, Yan W, Zhou L . Retrospective analysis of prognostic factors in patients of papillary thyroid microcarcinoma. Oncotarget. 2018; 9(85):35553-35558. PMC: 6238975. DOI: 10.18632/oncotarget.26248. View

17.

Park Y, Wang S, Lee J, Shin D, Kim I, Son S . Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: A prognostic factor of locoregional recurrence. Head Neck. 2015; 38 Suppl 1:E1172-6. DOI: 10.1002/hed.24186. View

18.

Chen S, Niu C, Peng Q, Tang K . Sonographic Characteristics of Papillary Thyroid Carcinoma With Coexistent Hashimoto's Thyroiditis in the Preoperative Prediction of Central Lymph Node Metastasis. Front Endocrinol (Lausanne). 2021; 12:556851. PMC: 8008373. DOI: 10.3389/fendo.2021.556851. View

19.

Jin K, Li L, Liu Y, Wang X . The characteristics and risk factors of central compartment lymph node metastasis in cN0 papillary thyroid carcinoma coexistent with Hashimoto's thyroiditis. Gland Surg. 2021; 9(6):2026-2034. PMC: 7804536. DOI: 10.21037/gs-20-699. View

20.

Feng Y, Min Y, Chen H, Xiang K, Wang X, Yin G . Construction and validation of a nomogram for predicting cervical lymph node metastasis in classic papillary thyroid carcinoma. J Endocrinol Invest. 2021; 44(10):2203-2211. DOI: 10.1007/s40618-021-01524-5. View